Program
ixekizumab
Also written as “Ixekizumab”, “LY2439821” and “80 mg ixekizumab”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Spondylarthritis · Arthritis, Rheumatoid · Axial Spondyloarthritis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 361 open or running | phase 4since May 4, 2017 | Aug 25, 2009 | none ahead |
| Celltrion | 11 open or running | phase 1since Sep 23, 2025 | Sep 23, 2025 | none ahead |
| Samsung Bioepis | 11 open or running | phase 1since Aug 20, 2026 | Aug 20, 2026 | Jun 9, 2027phase 1 · NCT07789964 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 23 studies since Aug 25, 2009.
- Mar 3, 2017Phase 1 study in PsoriasisEli Lilly · NCT03073213 · 32 enrolled · China
- Mar 3, 2017Phase 3 study in Plaque PsoriasisEli Lilly · NCT03073200 · 201 enrolled · United States, Argentina, Canada and more
- Apr 3, 2017Phase 3 study in Axial SpondyloarthritisEli Lilly · NCT03129100 · 773 enrolled · United States, Argentina, Austria and more
- May 4, 2017Phase 4 study in Arthritis, PsoriaticEli Lilly · NCT03151551 · 566 enrolled · Argentina, Australia, Austria and more
- Nov 9, 2017Phase 3 study in Skin DiseasesEli Lilly · NCT03364309 · 438 enrolled · China
- Jun 20, 2018Phase 4 study in Plaque PsoriasisEli Lilly · NCT03573323 · 1,027 enrolled · United States, Canada, Puerto Rico
- Feb 19, 20192 phase 1 studies in HealthyEli Lilly · NCT03848416, NCT03848403
- May 7, 2019Phase 4 study in PsoriasisEli Lilly · NCT03942042 · 12 enrolled · Japan
- Feb 5, 2020Phase 1 study in HealthyEli Lilly · NCT04259346 · 245 enrolled · United States
- Feb 19, 2020Phase 3 study in SpondylarthritisEli Lilly · NCT04285229 · 147 enrolled · China
- Aug 24, 2020Phase 3 study in Arthritis, JuvenileEli Lilly · NCT04527380 · 101 enrolled · Argentina, Belgium, Czechia and more
- May 4, 2023Phase 4 study in Arthritis, PsoriaticEli Lilly · NCT05855967 · 250 enrolled · India
- Sep 23, 2025Celltrion's first study: phase 1 study in Healthy ParticipantsNew to CelltrionCelltrion · NCT07200986 · 218 enrolled · South Korea
- Aug 20, 2026Samsung Bioepis's first study: phase 1 study in HealthyNew to Samsung BioepisSamsung Bioepis · NCT07789964 · 174 planned · South Korea
Ahead
- Jun 9, 2027Primary completion: phase 1 study in HealthySamsung Bioepis · NCT07789964
TargetBeta
“Interleukin 17A inhibitor”ChEMBL 37, by rule
Other programs on IL17A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| secukinumabrule | Novartis | phase 4 | 128 |
| vunakizumabrule | Jiangsu HengRui Medicine | phase 4 | 17 |
| bimekizumabrule | UCB | phase 3 | 43 |
| sonelokimabrule | moonlake-immunotherapeutics-ag | phase 3 | 12 |
| tibulizumabrule | Eli Lilly | phase 2 | 5 |
| SCT650Crule | Sinocelltech Group | phase 2 | 3 |
| UA026rule | usynova-pharmaceuticals-ltd | phase 1 | 1 |
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07789964Healthy · South Korea | 1 | Recruiting | Samsung Bioepis | Jun 9, 2027 | 174 |
| NCT07200986Healthy Participants · South Korea | 1 | Active, not recruiting | Celltrion | Mar 31, 2026 | 218 |
| NCT05855967Arthritis, Psoriatic · India | 4 | Completed | Eli Lilly | Aug 8, 2024 | 250 |
| NCT04527380Arthritis, Juvenile · Argentina, Belgium, Czechia and more | 3 | Active, not recruiting | Eli Lilly | Feb 19, 2024 | 101 |
| NCT04285229Spondylarthritis · China | 3 | Completed | Eli Lilly | Mar 31, 2021 | 147 |
| NCT04259346Healthy · United States | 1 | Completed | Eli Lilly | Feb 19, 2021 | 245 |
| NCT03942042Psoriasis · Japan | 4 | Completed | Eli Lilly | Jul 22, 2020 | 12 |
| NCT03848416Healthy · United States | 1 | Completed | Eli Lilly | Jun 7, 2019 | 99 |
| NCT03848403Healthy · United States | 1 | Terminated | Eli Lilly | Jul 18, 2019 | 70 |
| NCT03573323Plaque Psoriasis · United States, Canada, Puerto Rico | 4 | Completed | Eli Lilly | Jul 15, 2019 | 1,027 |
| NCT03364309Skin Diseases · China | 3 | Completed | Eli Lilly | Jun 4, 2020 | 438 |
| NCT03151551Arthritis, Psoriatic · Argentina, Australia, Austria and more | 4 | Completed | Eli Lilly | Nov 15, 2018 | 566 |
| NCT03129100Axial Spondyloarthritis · United States, Argentina, Austria and more | 3 | Completed | Eli Lilly | May 26, 2020 | 773 |
| NCT03073213Psoriasis · China | 1 | Completed | Eli Lilly | May 14, 2019 | 32 |
| NCT03073200Plaque Psoriasis · United States, Argentina, Canada and more | 3 | Completed | Eli Lilly | Feb 7, 2019 | 201 |
| NCT02993471Psoriasis · United States | 1 | Completed | Eli Lilly | Nov 21, 2017 | 28 |
| NCT02757352Axial Spondyloarthritis · United States, Argentina, Austria and more | 3 | Completed | Eli Lilly | Mar 1, 2019 | 303 |
| NCT02718898Psoriasis · United States, Australia, Austria and more | 3 | Completed | Eli Lilly | Feb 22, 2017 | 149 |
| NCT02696798Spondylarthritis · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | May 18, 2018 | 316 |
| NCT02696785Spondylarthritis · United States, Czechia, Germany and more | 3 | Completed | Eli Lilly | Dec 8, 2017 | 341 |
| NCT02634801Plaque Psoriasis · Germany | 3 | Completed | Eli Lilly | Nov 29, 2016 | 162 |
| NCT02584855Arthritis, Psoriatic · United States, Bulgaria, Czechia and more | 3 | Completed | Eli Lilly | Oct 30, 2018 | 394 |
| NCT02561806Plaque Psoriasis · Austria, Belgium, Canada and more | 3 | Completed | Eli Lilly | May 2016 | 302 |
| NCT02543918Healthy · United States | 1 | Completed | Eli Lilly | Nov 2015 | 84 |
| NCT02513550Plaque Psoriasis · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Nov 2016 | 1,257 |
| NCT02387801Psoriasis · United States | 3 | Completed | Eli Lilly | Sep 2015 | 12 |
| NCT02349295Arthritis, Psoriatic · United States, Australia, Czechia and more | 3 | Completed | Eli Lilly | Sep 9, 2016 | 363 |
| NCT01870284Spondylitis, Ankylosing · United States, Argentina, Belgium and more | 3 | Withdrawn | Eli Lilly | Apr 2016 | 0 |
| NCT01777191Plaque Psoriasis · United States, Puerto Rico | 3 | Completed | Eli Lilly | May 2014 | 204 |
| NCT01695239Arthritis, Psoriatic · United States, Belgium, Bulgaria and more | 3 | Completed | Eli Lilly | Dec 2014 | 417 |
| NCT01646177Psoriasis · United States, Argentina, Bulgaria and more | 3 | Completed | Eli Lilly | May 22, 2014 | 1,346 |
| NCT01624233Psoriasis · Japan | 3 | Completed | Eli Lilly | Sep 2013 | 91 |
| NCT01597245Psoriasis · United States, Australia, Austria and more | 3 | Completed | Eli Lilly | Mar 25, 2014 | 1,224 |
| NCT01474512Psoriasis · United States, Australia, Canada and more | 3 | Completed | Eli Lilly | Jun 24, 2014 | 1,296 |
| NCT01253265Arthritis, Rheumatoid · Japan | 1 | Completed | Eli Lilly | Dec 2011 | 32 |
| NCT01236118Arthritis, Rheumatoid · Japan | 1 | Completed | Eli Lilly | Jan 2013 | 28 |
| NCT01107457Psoriasis · United States, Denmark | 2 | Completed | Eli Lilly | Jan 2011 | 142 |
| NCT00966875Arthritis, Rheumatoid · United States, Argentina, Chile and more | 2 | Completed | Eli Lilly | Mar 2011 | 448 |
How it is read
Names in the registry
- “Ixekizumab”, 29 entries
- “LY2439821”, 3 entries
- “80 mg ixekizumab”, 2 entries
- “Ixekizumab 80 mg Q4W”, 1 entry
- “Ixekizumab 80 mg Q2W”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 16 studies
- Arthritis, Psoriatic, 5 studies
- Spondylarthritis, 3 studies
- Arthritis, Rheumatoid, 3 studies
- Axial Spondyloarthritis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.